Information, not a decision

Triple-negative breast cancer: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 14 Nov 2026

Open trials (478)

NCT07069595	Phase 2	PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease	Recruiting
NCT05422794	Phase 1	Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer	Recruiting
NCT03606967	Phase 2	Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	Recruiting
NCT05111561	Phase 1	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Recruiting
NCT06270706	Phase 1	A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors	Recruiting
NCT07723469	Phase 3	Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery	Not yet recruiting
NCT07297667	Phase 1	GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours	Recruiting
NCT06841354	Phase 3	A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)	Recruiting
NCT07503808	Phase 1	A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types	Recruiting
NCT07423117	Phase 1	A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy	Recruiting
NCT06966700	Phase 3	A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)	Recruiting
NCT07652242	Phase 1	Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer	Recruiting

466 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

No phase 3 trial in this list ended in the last 90 days.

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 14 Nov 2026

https://frontlightresearch.com/en/doctor/triple-negative-breast-cancer/tumor-board